Analysts’ Top Healthcare Picks: Charles River Labs (CRL), Harrow Health (HROW)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Charles River Labs (CRL – Research Report), Harrow Health (HROW – Research Report) and Insulet (PODD – Research Report) with bullish sentiments.
President's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Charles River Labs (CRL)
Jefferies analyst David Windley maintained a Buy rating on Charles River Labs today and set a price target of $225.00. The company’s shares closed last Wednesday at $158.00, close to its 52-week low of $150.79.
According to TipRanks.com, Windley is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Charles River Labs with a $222.13 average price target, a 51.3% upside from current levels. In a report released today, TipRanks – PerPlexity also upgraded the stock to Buy with a $175.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Harrow Health (HROW)
In a report released today, Mayank Mamtani from B. Riley Securities maintained a Buy rating on Harrow Health, with a price target of $74.00. The company’s shares closed last Wednesday at $49.87.
According to TipRanks.com, Mamtani is a 3-star analyst with an average return of
Harrow Health has an analyst consensus of Strong Buy, with a price target consensus of $69.00, representing a 37.7% upside. In a report issued on February 12, William Blair also maintained a Buy rating on the stock.
Insulet (PODD)
In a report released today, Danielle Antalffy from UBS reiterated a Buy rating on Insulet, with a price target of $400.00. The company’s shares closed last Wednesday at $258.07.
According to TipRanks.com, Antalffy is a 4-star analyst with an average return of
Insulet has an analyst consensus of Strong Buy, with a price target consensus of $353.47, a 32.9% upside from current levels. In a report released today, TipRanks – DeepSeek also upgraded the stock to Buy with a $285.00 price target.
